As brain science moves from research labs into operating rooms and rehabilitation centres, Brain–Computer Interface (BCI) technologies are beginning to reshape how clinicians diagnose, monitor, and treat neurological conditions. With continuous monitoring, AI-driven insights and neurotechnology converging, healthcare systems must rethink decision-making, safety and long-term patient care. In this exclusive conversation, Abhijeet Satani, Research Scientist and Inventor of the Brain-Computer Interface (BCI), shares with Dr Asawari Savant of Elets News Network (ENN), how BCIs and neural interfaces could redefine mainstream healthcare over the next five years. Edited excerpts 

Post a decade pioneering Brain–Computer Interface (BCI) research with patents across the US, Europe, China, and India, how do you see BCIs transforming clinical decision-making and patient outcomes in mainstream healthcare over the next five years?

The real impact of BCIs won’t come from dramatic breakthroughs; it’ll come from quieter, better decisions. The brain gives off early warning signals long before symptoms show up, and BCIs allow clinicians to see those signals in real time. Over the next five years, they’ll increasingly act as decision support tools, flagging cognitive stress, loss of motor intent, or early neurological decline before it becomes obvious at the bedside. That shift toward earlier, physiology-led decisions can significantly improve outcomes without adding more burden on clinicians.

The wireless EEG-based Brain Control Interface Module provides real-time data to surgeons during brain surgeries. From a hospital and healthcare systems perspective, how does this innovation improve safety, efficiency, and cost-effectiveness in neurosurgical procedures?

Neurosurgery is ultimately about managing uncertainty in real time. Real-time EEG was designed to reduce that uncertainty at critical moments. From a hospital’s perspective, it improves safety by continuously monitoring brain function instead of relying on intermittent checks. It improves efficiency by shortening pauses and decision loops during surgery. And over time, it reduces costs by lowering complication rates, reoperations, and extended ICU stays. Small improvements during surgery compound into large system-level gains.

Prosthetics and paralysis rehabilitation remain critical challenges in healthcare. How has your work on EMG-based exoskeletons moved us closer to scalable, commercially viable solutions for rehabilitation centres and medical institutions?

Rehab doesn’t work well when technology takes over instead of tuning into the body. EMG signals matter because they reflect intention long before movement becomes visible. Our focus was on translating that intent into an assisted motion that feels intuitive rather than mechanical. When patients feel the system is responding to them, engagement improves. 

For rehabilitation centres, this means shorter learning curves, less clinician involvement, and more consistent use. At scale, rehab works best when it follows how the nervous system naturally learns to move again, not when it relies on complex machines.

While blended neuroscience, robotics, AI and design thinking in your research, how important is interdisciplinary innovation for healthcare organisations looking to stay future-ready in an increasingly tech-driven ecosystem?

The brain doesn’t operate in silos, and healthcare innovation shouldn’t either. The most resilient organisations are the ones that integrate neuroscience, AI, engineering, and design thinking early, not as add-ons. Interdisciplinary work reduces blind spots. Many health-tech failures aren’t scientific; they’re human, operational, or ethical failures that could’ve been avoided with broader thinking.

Projects like Sensorium and Plant-to-Human Interfaces explore non-traditional data sources and human–technology interaction. What lessons can digital health companies draw from these experiments when designing next-generation patient monitoring systems?

These experiments reinforced a simple truth: more data doesn’t mean better understanding. Non-traditional interfaces force you to ask what signals actually matter. Many digital health systems overwhelm users with information that isn’t actionable. The real lesson is to design monitoring tools that prioritise signal quality, context, and timing, so clinicians and patients can respond intuitively, not cognitively overload themselves.

The glucose-monitoring implant highlights both innovation and transparency. What are your suggestions on balancing rapid innovation with ethical responsibility and patient safety?

Living with your own technology changes how you think about risk and responsibility. Self-experimentation can drive empathy and transparency, but it can’t replace structured safeguards. Health-tech companies need clear boundaries between rapid experimentation and patient-facing deployment. Innovation moves fast, but trust moves slowly, and once it’s lost, it’s very hard to regain in healthcare.

As healthcare moves toward continuous monitoring and predictive care, how do you see implantable and non-invasive neural sensors reshaping chronic disease management, especially for conditions like diabetes and neurological disorders?

Many chronic diseases unfold quietly before they’re ever diagnosed. Continuous neural and metabolic monitoring allows us to catch those gradual changes early on. In diabetes, it uncovers how stress, sleep and cognition shape glucose levels, not just what we eat. In neurological disorders, small signal shifts can indicate decline long before any symptoms appear. When we focus on trends instead of snapshots, care becomes more human and less reactive. 

Also read: Reimagining Healthcare Financing in India’s Out-of-Pocket Economy

Looking ahead, what advice would you give to healthcare enterprises, med-tech startups and policy-makers aiming to invest in brain science and neurotechnology as a strategic growth area for India’s healthcare future?

The real opportunity for neurotechnology in India lies in addressing local, real-world problems, at scale. That means backing translational research and building tools that function in everyday hospital settings, not just controlled labs. Startups should prioritise ease of use and affordability over novelty. Policymakers can support this by enabling responsible experimentation without lowering safety standards. India won’t lead by imitation; it will lead by building neurotech that fits real clinical life.

Like

Dislike

Be a part of Elets Collaborative Initiatives. Join Us for Upcoming Events and explore business opportunities. Like us on Facebook , connect with us on LinkedIn and follow us on Twitter , Instagram.

"Exciting news! Elets technomedia is now on WhatsApp Channels Subscribe today by clicking the link and stay updated with the latest insights!" Click here!